L
LenioBio
Biotech & Life Sciences · Düsseldorf, Germany · Founded 2016
World's most powerful platform aiding CFPS researchers express difficult-to-express proteins \u0026 get up to 30x more protein per euro spent. Learn more here MoreLess
LenioBio GmbH is a biotechnology startup based in Düsseldorf, Germany, specializing in protein expression technology. The company has developed a proprietary platform called ALiCE, which stands for "Active Lysate for In vitro Expression." This platform is designed to produce complex proteins that are typically difficult to express using traditional methods. ALiCE leverages intact organelles, such as active mitochondria and reformed endoplasmic reticulum, to provide a continuous energy supply and enable the proper folding and glycosylation (a process where sugars are added to proteins) of complex proteins. This results in significantly higher yields of protein production compared to other cell-free systems.
LenioBio serves a diverse range of clients, including pharmaceutical companies, academic research institutions, and biotech firms. These clients require high-quality proteins for various applications, such as drug development, diagnostics, and research. The market LenioBio operates in is the global biotechnology and life sciences sector, which is continually growing due to advancements in medical research and the increasing demand for innovative therapeutic solutions.
The business model of LenioBio revolves around selling its ALiCE protein expression kits and providing custom protein production services. The company generates revenue by offering these products and services to its clients, who benefit from the high efficiency and scalability of the ALiCE platform. Additionally, LenioBio has secured funding through grants, such as the prestigious Horizon 2020 SME 2 Grant, which supports the acceleration and scaling up of its technology.
In summary, LenioBio is a pioneering biotech company that simplifies the production of complex proteins, serving a wide range of clients in the life sciences industry. Its innovative ALiCE platform offers a scalable and efficient solution for protein expression, positioning the company for continued growth and success.
Keywords: Biotechnology, Protein Expression, ALiCE Platform, Complex Proteins, Life Sciences, Pharmaceutical, Research, Custom Services, High Yield, Innovation.
Company overview
LenioBio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Düsseldorf, Germany
- Employees
- 48
- Open positions
- None listed
- Dealroom signal
- 68.0
Valuation & funding
LenioBio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jul 2025 | $4.1M | — | European Health and Digital Executive Agency | ↗ |
| EARLY VC✓Equity / VC | Dec 2024 | $0 | — | Bridford Group | — |
| GRANTOther financing | Sep 2023 | $0 | — | EIT Food | ↗ |
| SERIES A✓Equity / VC | Mar 2022 | $13M | $51M | Bridford Group | ↗ |
| GRANT✓Other financing | Jun 2021 | $434K | — | Undisclosed | — |
| SUPPORT PROGRAM✓Other financing | Dec 2020 | EIT Health | — | ||
| SPINOUT✓Other financing | Jan 2016 | Fraunhofer Venture · Fraunhofer Society - Fraunhofer Gesellschaft | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $354K | 0% | −$8.7M | -2459.1% |
| 2025 | $354K | 0% | −$8.7M | -2459.1% |
| 2024 | $354K | 0% | −$8.7M | -2459.1% |
| 2023 | $354K | +2.3% | ||
| 2022 | $346K | +31.1% | ||
| 2021 | $264K | +18.7% | ||
| 2020 | $222K | — |
Growth signals
LenioBio website traffic
Latest recorded traffic for LenioBio is 4.6K monthly website visits, up 91.7% over the last three months. LenioBio's team declined 4% over the past year.
Comparisons
LenioBio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Bac3Gel3D mucus models and beads for microbiome R&D. |
Oeiras, Portugal | Operational | 13 | $1.6M | $28M |
 Cellbox LabsDeveloping organs on a chip that are miniature organ replicas outside human body |
Riga, Latvia | Operational | |||
 THERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care |
Paris, France | Operational | |||
 DeloxCompact, automatic bio-decontamination equipment for critical environments. |
Lisbon, Portugal | Operational | |||
 VitaDXDeveloping a solution for the early detection of bladder cancer |
Paris, France | Operational | |||
 ConfocalAims to change the microscopy industry with a confocal microscope based on the re-scan invention |
Amsterdam, Netherlands | Operational | |||
 Aenitis TechnologiesDeveloping a cell treatment device |
Paris, France | Operational | |||
 BioSerenityLeading global providers of remote diagnostic solutions |
Paris, France | Operational |
Talent graph
LenioBio's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on LenioBio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where LenioBio has talent and traffic
team presence
In the news
Latest news about LenioBio
Recent press, funding announcements, and product moves mentioning LenioBio — open to read from the original sources.
Market sentiment
What the market is saying about LenioBio
An AI-synthesized read of the highest-engagement posts about LenioBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LenioBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.